Please login to the form below

Not currently logged in
Email:
Password:

Kybella

This page shows the latest Kybella news and features for those working in and with pharma, biotech and healthcare.

Allergan adds Zeltiq to M&A roster in $2.48n deal

Allergan adds Zeltiq to M&A roster in $2.48n deal

Other deals in the aesthetics sector include Allergan's $2.1bn purchase of Kythera in 2015, bringing in double chin-reducing therapy Kybella (deoxycholic acid), and the takeover of regenerative medicine

Latest news

  • Allergan buys regenerative medicine firm LifeCell for $2.9bn Allergan buys regenerative medicine firm LifeCell for $2.9bn

    Those are headed by blockbuster wrinkle treatment Botox but also include Kybella - bought along with Kythera last year for $2.1bn - for reducing double chins and dermal filler Juvederm.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... Kybella. submental contouring (double chin).

  • Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

    Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera. Company will add Kythera’ s double chin therapy Kybella to its portfolio. ... The company's chief executive Brent Saunders also suggested Allergan would be able to speed up the international

  • Kythera bags FDA approval for double chin therapy Kythera bags FDA approval for double chin therapy

    Perhaps mindful that Kybella could also be a target, Kythera is launching the product with a holographic label that will make it easier for healthcare practitioners to identify genuine product. ... Kythera has also filed for approval of Kybella in Canada,

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    When Kybella is injected into subcutaneous fat, it causes the destruction of fat cells and, once destroyed, these cells cannot store or accumulate fat. ... Kythera Biopharmaceuticals/ Allergan. Rx aesthetic medicine products - incl Kybella for double

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics